VolitionRx Ltd

VNRX

Market cap $15.7M

HENDERSON, Nev., July 7, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces the release of a new clinical study demonstrating the significant prognostic value of its Nu.Q® Cancer Assay in newly diagnosed lung cancer patients, which could help clinicians identify patients' likely outcomes and personalize treatment selection accordingly.

HENDERSON, Nev., June 17, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces a collaboration with Sysmex (TYO: 6869), a leader in global in vitro diagnostics, to optimize Volition's Nu.Q® NETs H3.1 assay on the Sysmex platform.

$4.6 million upfront with up to an additional $2.3 million of potential aggregate gross proceeds upon the full exercise of warrants HENDERSON, Nev., June 7, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announced the pricing of its previously announced public offering of 2,960,000 shares of common stock, and warrants to purchase up to an aggregate of 1,480,000 shares of common stock, at a combined public offering price of $1.55 per share and accompanying half warrant.

Seeks Strategic Partners to Deploy Nu.Q® Platform in Outbreak Zones HENDERSON, Nev., June 3, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces that it has expanded its robust intellectual property portfolio by filing a strategic patent application covering the use of its proprietary Nu.Q® technology in triaging and monitoring patients who are suspected of having contracted the Ebola virus.

Update Highlights 300% Q1 Revenue Growth, Advance Toward $5 Million Veterinary Milestone, and Active Licensing Discussions with More Than a Dozen Global Diagnostic Leaders HENDERSON, Nev., May 27, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today provided a comprehensive corporate update highlighting the significant clinical and commercial progress achieved over recent months.

VolitionRx Limited (VNRX) Q1 2026 Earnings Call Transcript

Conference call to discuss financial and operational results scheduled for  Friday, May 15 at 8:30 a.m. U.S. Eastern Time HENDERSON, Nev.

Conference call to take place on Friday, May 15 at 8:30 a.m. U.S Eastern Time HENDERSON, Nev.

The publication of this study in a peer reviewed journal is expected subsequently to unlock a $5 million contractual milestone payment HENDERSON, Nev., May 6, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces submission for peer review a clinical manuscript1 reporting the high accuracy of its Nu.Q® Vet Feline prototype assay in detecting lymphoma in cats, the most common cancer in the species2.

HENDERSON, Nev., April 29, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces a major technical milestone with the successful detection of nucleosomes in capillary blood from critically ill sepsis patients using its lateral flow prototype.